TARS insider trading — Tarsus Pharmaceuticals, Inc.
No open-market insider purchases or sales were filed for Tarsus Pharmaceuticals, Inc. (TARS) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent TARS insider transactions
Every Form 4 filed by Tarsus Pharmaceuticals, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Pyott David E I | Director | M · Option exercise | Indirect | 201 | — | — | Form 4 |
| Sep 15, 2026 | Yarno Wendy L | Director | M · Option exercise | Direct | 302 | — | — | Form 4 |
| Sep 15, 2026 | Link William J Phd | Director | M · Option exercise · 10b5-1 | Direct | 201 | — | — | Form 4 |
| Sep 15, 2026 | Link William J Phd | Director | S · Sale · 10b5-1 | Direct | 12,500 | $78.38 | $980K | Form 4 |
| Sep 4, 2026 | Azamian Bobak R. | President/CEO and Board Chair | S · Sale · 10b5-1 | Indirect | 10,000 | $90.56 | $906K | Form 4 |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 10,773 | $87.50 | $943K | Form 4 |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | S · Sale · 10b5-1 | Indirect | 3,180 | $87.50 | $278K | Form 4 |
| Sep 4, 2026 | Neervannan Seshadri | Chief Operating Officer | S · Sale · 10b5-1 | Direct | 4,564 | $85.00 | $388K | Form 4 |
| Sep 2, 2026 | Azamian Bobak R. | President/CEO and Board Chair | S · Sale · 10b5-1 | Indirect | 10,000 | $80.06 | $801K | Form 4 |
| Sep 2, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 5,387 | $80.00 | $431K | Form 4 |
| Sep 2, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | S · Sale · 10b5-1 | Indirect | 1,590 | $80.00 | $127K | Form 4 |
| Sep 1, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 4,601 | $73.86 | $340K | Form 4 |
TARS insider trading FAQ
Are insiders buying TARS stock?
Not on the open market. In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading TARS?
No insider bought or sold on the open market in the last 90 days.
Where does TARS insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.